Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Montana: below-average open trial sites
56 of 250 in-state trials are recruiting (22%); below the 37% national average by 15 percentage points.
According to ClinicalTrials.gov-derived indexes, Montana sits in the lower half of US states by in-state trial count (#48 of 52 states by registered in-state trial count).
Montana: 250 US clinical trials with in-state sites, 56 recruiting.
Montana has 250 registered US clinical trials with a study site in-state, 56 of them currently recruiting (below the 37% national average by 15 percentage points). 83 of these trials are in Phase 3 (late-stage) and 77 in Phase 2. The most frequently studied condition in Montana is Non-Small Cell Lung Cancer, with 14 linked trials.
Thin-volume Montana archive
Montana open-enrollment share is 22% (p2 of states with sites; national baseline 37%). Treat this page as a compact local index (thin-volume · low-open), then jump to recruiting trials or methodology rather than expecting hub-scale coverage.
Below-average open enrollment
Montana still shows 56 recruiting of 250 in-state trials (22% open), but below the 37% national average by 15 percentage points, so archived statuses weigh heavier than the national baseline.
- 22%
- open (below national share)
- 56
- still recruiting despite cool share
- 77
- Phase 2 rows in this footprint
- 14
- top: Non-Small Cell Lung Cancer
Recruiting share is below the 37% national average by 15 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Montana vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
250 Top 92% more indexed trials than 8% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Montana on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Montana open-enrollment share sits below the national baseline.
56 of 250 in-state trials (22.4%) are recruiting, against 37% nationally (-14.6 percentage points). Counts include every study with at least one recorded site in the state.
-
Montana trial sites spread across 6 city hubs.
Billings lists 88 of 250 in-state trials (35.2%) across 58 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Non-Small Cell Lung Cancer is the most-studied condition in Montana.
14 of 250 in-state trials (5.6%) list Non-Small Cell Lung Cancer. That is a local concentration figure, not a national disease ranking.
-
Montana sponsorship is fragmented across many organizations.
University of Montana appears on 15 of 250 in-state trials (6%). Sponsor identity is as filed on ClinicalTrials.gov.
-
Most Montana indexed trials have already finished enrollment.
144 of 250 (57.6%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 144 |
| Recruiting | 56 |
| Active | 50 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 3 | 83 |
| Phase 2 | 77 |
| NA | 41 |
| Phase 1 | 19 |
| Phase 4 | 8 |
| Early Phase 1 | 2 |
Top Conditions
Top Sponsors
Where trials run in Montana
Billings carries 88 of Montana's 250 indexed trials (35%) across 58 named sites, ahead of Missoula at 60. 6 cities clear five listed trials, together naming 151 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Billings | 88 | 58 |
| Missoula | 60 | 28 |
| Butte | 37 | 18 |
| Bozeman | 27 | 22 |
| Great Falls | 19 | 15 |
| Kalispell | 14 | 10 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Open-share low
Montana open-enrollment share is 22% (p2 of states with sites; national baseline 37%).
Montana: open share sits in the low tercile of states
Sites spread across 6 cities with five or more listed trials, led by Billings (88, 35% of the state total) and Missoula (60), together naming 151 distinct research locations.
Phase mix: 83 Phase 3 vs 77 Phase 2 (balanced across stages).
Top condition: Non-Small Cell Lung Cancer (14 trials); top sponsor University of Montana (15).
thin-volume · low-open figures (250 trials · 22% open) describe registry geography under the open-share low read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Montana on open-enrollment share
Cross-state peers under the open-share low read (thin-volume · low-open), not the same-state browse list.
Similar thin-volume peers (± open share)
- South Dakota · 273 trials · 31% recruiting
- West Virginia · 277 trials · 36% recruiting
- Vermont · 191 trials · 31% recruiting
- New Hampshire · 471 trials · 33% recruiting
- Wyoming · 17 trials · 35% recruiting
Similar low-open peers (± trial volume)
- Maine · 23% recruiting · 315 trials
- Alaska · 25% recruiting · 485 trials
- Hawaii · 26% recruiting · 437 trials
- North Dakota · 19% recruiting · 235 trials
- Idaho · 26% recruiting · 633 trials